Original Article
Leukemia (2006) 20, 1963–1966. doi:10.1038/sj.leu.2404409; published online 28 September 2006
Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias
T Palomero1,2, K McKenna3, J O-Neil3, I Galinsky4, R Stone4, K Suzukawa5, E Stiakaki6, M Kalmanti6, E A Fox7, M A Caligiuri8, J C Aster9, A T Look3 and A A Ferrando1,2,10
- 1Institute for Cancer Genetics, Columbia University, New York, NY, USA
- 2Department of Pathology, Columbia University Medical Center, New York, NY, USA
- 3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA, USA
- 4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA, USA
- 5Clinical and Experimental Hematology Department, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
- 6Department of Pediatric Hematology-Oncology, University of Crete, Heraklion Crete, Greece
- 7Molecular Diagnostics Laboratory, Microarray Core, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA
- 8Internal Medicine-Hematology Oncology Department, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
- 9Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
- 10Department of Pediatrics, Columbia University Medical Center, New York, NY, USA
Correspondence: Dr AA Ferrando, Institute for Cancer Genetics, Columbia University, 1130 St Nicholas Avenue, Room 901B, New York, NY 10032, USA. E-mail: af2196@columbia.edu
Received 29 June 2006; Revised 11 August 2006; Accepted 17 August 2006; Published online 28 September 2006.
Abstract
Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines. We found activating mutations in NOTCH1 in a single M0 primary AML sample, in three (ML1, ML2 and CTV-1) out of 23 AML cell lines and in the diagnostic (myeloid) and relapsed (T-lymphoid) clones in a patient with lineage switch leukemia. Importantly, the ML1 and ML2 AML cell lines are derived from an AML relapse in a patient initially diagnosed with T-ALL. Overall, these results demonstrate that activating mutations in NOTCH1 are mostly restricted to T-ALL and are rare in AMLs. The presence of NOTCH1 mutations in myeloid and T-lymphoid clones in lineage switch leukemias establishes the common clonal origin of the diagnostic and relapse blast populations and suggests a stem cell origin of NOTCH1 mutations during the molecular pathogenesis of these tumors.
Keywords:
NOTCH1, AML, leukemia stem cells
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Choline transport by neuroblastoma cells in tissue culture
Nature Letters to Editor (06 Dec 1974)
Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias
Leukemia Original Article
Genetic segregation of microsatellite markers in Saccharum officinarum and S. spontaneum
Heredity Original Article
